Human Cytomegalovirus: From Molecular Pathogenesis to Therapeutic Innovations
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 642
Special Issue Editors
Interests: human cytomegalovirus; glioblastoma; targets; biomarkers; biotherapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human cytomegalovirus (HCMV) or human herpesvirus 5 is a ubiquitous herpesvirus that infects a large proportion of the global population. It remains asymptomatic in most healthy individuals, but it is one of the most important causes of complications in immunocompromised patients (patients with AIDS and solid organ transplant or hematopoietic stem cell transplant recipients) and those with congenital infections. HCMV could also represent an interesting target for treatment to limit the progression of glioblastoma, a highly aggressive tumor.
HCMV encodes a variety of gene products that regulate a wide array of cellular and immune pathways. However, there are still significant gaps in our understanding of how these gene products contribute to viral persistence and pathogenesis. Furthermore, the currently used antivirals, for which efficacy has been demonstrated, exhibit significant toxicity, and, most importantly, numerous resistances to these treatments have emerged. Therefore, it is essential to identify new therapeutic targets.
This Special Issue will focus on recent advances in understanding the pathogenesis of HCMV, its interactions with the host cells and new developments in therapeutic strategies.
Dr. Gaëtan Ligat
Dr. Alexia Damour
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human cytomegalovirus
- therapeutic strategies and vaccines
- glioblastoma
- congenital infection
- immunocompromised
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
